TL;DR
This study reveals significant disparities in hepatocellular carcinoma (HCC) survival in China based on health insurance status. Patients covered by the Urban and Rural Resident Basic Medical Insurance (URRBMI) experienced substantially worse survival outcomes compared to those with Urban Employee Basic Medical Insurance (UEBMI), even after accounting for various clinical and demographic factors. This highlights a critical need to address healthcare inequities linked to China's diverse insurance schemes.
What Problem Does This Paper Address?
Hepatocellular carcinoma (HCC) is a major global health challenge, particularly prevalent in China. While advancements in treatment exist, access to and utilization of healthcare can be significantly influenced by socioeconomic factors, including health insurance. China has a multi-tiered basic medical insurance system, with the Urban Employee Basic Medical Insurance (UEBMI) generally offering better benefits than the Urban and Rural Resident Basic Medical Insurance (URRBMI). However, the extent to which these insurance disparities translate into differences in survival for HCC patients in China has not been thoroughly investigated. This paper aims to fill that gap by examining HCC survival rates in relation to these two primary insurance types in Tianjin, China.
Methods
The researchers conducted a retrospective population-based study using data from the Tianjin Basic Medical Insurance claims database. They identified adult patients newly diagnosed with HCC between 2011 and 2016 and followed them until death, withdrawal from insurance, or the end of the study period (December 31, 2017).
Key analytical techniques included:
- Kaplan-Meier analysis: To estimate and visualize overall survival curves for different insurance groups.
- Six parametric models: Used to extrapolate survival curves beyond the observed follow-up period, providing a longer-term survival projection.
- Adjusted Cox proportional hazards models: This was the primary method for assessing the association between insurance status and survival. The models were progressively adjusted for a comprehensive set of covariates, including age, sex, baseline comorbidities (like liver cirrhosis, hepatitis), healthcare resource utilization (hospitalizations, outpatient visits), medical costs, tumor metastasis at diagnosis, initial treatment, and antiviral therapy.
- Propensity score matching: A sensitivity analysis was performed using this technique to further mitigate potential biases by creating comparable groups of patients based on observed characteristics.
Datasets
The study utilized data from the Tianjin Basic Medical Insurance claims database (2008-2017). This database contained information on inpatient, outpatient, and pharmacy claims, as well as patient demographics, enrollment history, dates of service, diagnoses (using ICD-10 codes), medical prescriptions, procedures, and associated costs. All-cause mortality data was linked to this database.
Key Insights and Ideas
- Insurance as a Social Determinant of Health: The study strongly suggests that health insurance status is a significant social determinant of health outcomes for HCC patients in China, impacting survival rates.
- URRBMI as a Marker for Worse Outcomes: Patients enrolled in URRBMI, which generally has less comprehensive coverage, faced a significantly higher risk of death compared to their UEBMI counterparts.
- Disparities Pre-dating Diagnosis: While insurance impacts treatment, the study's findings suggest that some survival disparities may exist even before diagnosis, potentially linked to differences in access to early screening or diagnostic pathways.
- Complexity of Survival Factors: The study meticulously adjusted for numerous factors, yet the insurance disparity persisted, underscoring the multifaceted nature of survival and the independent role of insurance.
Key Results
- A total of 2,068 patients were included: 1,468 under UEBMI and 570 under URRBMI.
- The median survival time for UEBMI patients was 37.8 months, significantly longer than the 12.2 months for URRBMI patients.
- 1-, 3-, and 5-year overall survival rates were considerably higher for UEBMI patients (63.8%, 51.0%, 44.4%) compared to URRBMI patients (50.2%, 33.4%, 22.8%).
- After adjusting for multiple confounders, patients covered by URRBMI had a 72% higher risk of death (HR: 1.72; 95% CI: 1.47–2.00) compared to UEBMI patients.
- This survival difference remained statistically significant even after propensity score matching (HR: 1.49; 95% CI: 1.21–1.83).
Limitations and Future Work
The authors acknowledge several limitations:
- Geographic Specificity: The study was conducted in Tianjin, and while the general differences in benefit packages between UEBMI and URRBMI are consistent across China, specific regional variations might exist.
- Lack of HCC-Specific Survival Data: The study focused on all-cause mortality, not HCC-specific survival, due to data limitations. However, they note that previous studies have shown similar trends for both outcomes.
- Limited Clinical Detail: The database did not collect detailed clinical characteristics like tumor stage, which could further explain survival differences.
- Socioeconomic Status (SES) and Health Behaviors: While some factors were adjusted for, a comprehensive assessment of SES (education, income, work status) and health behaviors (smoking, drinking) was not fully integrated, which could influence survival.
- Emerging Therapies: The study period predates widespread coverage of newer, expensive HCC treatments like Sorafenib, limiting the ability to assess their impact on insurance-related disparities.
Future work suggested includes:
- Further research to understand the specific mechanisms driving these disparities, potentially by examining reimbursement rates more deeply.
- Studies incorporating richer data on clinical characteristics, treatment details, and SES.
- Investigating disparities in access to screening, diagnosis, and advanced therapies across different insurance schemes.
Summary updated